3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
3
Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Advanced Malignancies
2
Urothelial Cancer
1
Thyroid Neoplasms
1
Solid Tumors, KRAS Mutation
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Prostatic Neoplasms
1
Prostate Cancer Metastatic
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Opioid-Related Disorders
1
Lung Neoplasms
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Leiomyosarcoma
1
KRAS p.G12C Mutant Advanced Solid Tumors
1
Hematologic Neoplasms
1
Healthy Adult Participants
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Cancer Pain
1
Interventions
Bevacizumab
119
Fluorouracil
91
Leucovorin
83
Cetuximab
83
Oxaliplatin
80
pembrolizumab
70
Irinotecan
67
Nivolumab
46
Capecitabine
43
Specimen Handling
40
regorafenib
30
Folfox protocol
29
trifluridine tipiracil drug combination
28
Magnetic Resonance Spectroscopy
27
Biopsy
27
Panitumumab
26
Standard of Care
25
HMPL-013
25
IFL protocol
21
Gemcitabine
20
Blood Specimen Collection
19
atezolizumab
18
Trifluridine
18
Cisplatin
18
tislelizumab
17
balstilimab
16
Colonoscopy
16
Carboplatin
16
encorafenib
15
Paclitaxel
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colorectal Neoplasms
×
Midazolam
×
1 year
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled